Capital International Inc. CA Cuts Position in Novo Nordisk A/S $NVO

Capital International Inc. CA lowered its stake in Novo Nordisk A/S (NYSE:NVO) by 62.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 87,935 shares of the company’s stock after selling 145,643 shares during the quarter. Capital International Inc. CA’s holdings in Novo Nordisk A/S were worth $4,474,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the stock. Capital International Investors grew its stake in shares of Novo Nordisk A/S by 52.4% in the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after buying an additional 6,092,192 shares in the last quarter. Franklin Resources Inc. grew its stake in shares of Novo Nordisk A/S by 4,190.8% in the third quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock valued at $776,016,000 after buying an additional 13,658,867 shares in the last quarter. State Street Corp grew its stake in shares of Novo Nordisk A/S by 1.0% in the third quarter. State Street Corp now owns 6,106,836 shares of the company’s stock valued at $340,125,000 after buying an additional 59,153 shares in the last quarter. Boston Partners acquired a new stake in shares of Novo Nordisk A/S in the third quarter valued at about $310,199,000. Finally, Northern Trust Corp grew its stake in shares of Novo Nordisk A/S by 4.3% in the third quarter. Northern Trust Corp now owns 4,611,126 shares of the company’s stock valued at $255,871,000 after buying an additional 189,640 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

NVO has been the subject of a number of recent research reports. Morgan Stanley upgraded Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price for the company in a research note on Tuesday, March 3rd. Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, May 12th. Wolfe Research began coverage on Novo Nordisk A/S in a research note on Thursday, March 26th. They set a “peer perform” rating for the company. Sanford C. Bernstein began coverage on Novo Nordisk A/S in a research note on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price objective for the company. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a research note on Monday, March 2nd. Four research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Trading Down 4.4%

NYSE:NVO opened at $41.05 on Tuesday. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The business’s 50 day moving average is $41.71 and its two-hundred day moving average is $46.12. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $81.44. The company has a market cap of $183.31 billion, a PE ratio of 9.64, a P/E/G ratio of 3.83 and a beta of 0.78.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The company had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. On average, analysts predict that Novo Nordisk A/S will post 3.46 EPS for the current year.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk said its oral Wegovy pill has surpassed 3 million U.S. prescriptions in just over five months, suggesting very strong adoption and broadening use among patients who had not previously taken a GLP-1 drug.
• Positive Sentiment: Real-world data reportedly show Ozempic 2 mg performing competitively against Eli Lilly’s Mounjaro on glucose control and weight-loss outcomes, which supports Novo’s diabetes franchise. Article: Novo Nordisk Real-World Data Supports Ozempic Against LLY’s Mounjaro
• Positive Sentiment: Novo also highlighted investigational zenagamtide data showing 14.6% weight loss in adults with type 2 diabetes, reinforcing optimism around its pipeline. Article: Novo Nordisk’s Investigational Zenagamtide Shows 14.6% Weight Loss In Adults With Type-2 Diabetes
• Positive Sentiment: The company continues its share repurchase program, which can help support earnings per share and signals management confidence. Article: Novo Nordisk A/S – share repurchase programme
• Neutral Sentiment: Several articles framed Novo and Lilly as locked in a major race for the GLP-1 pill market ahead of Medicare coverage decisions, underscoring the long-term opportunity but also the competitive risk. Article: Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
• Negative Sentiment: Eli Lilly’s oral GLP-1 pill reportedly outperformed rival therapies in late-stage diabetes trials, highlighting the competitive threat facing Novo Nordisk. Article: LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZeneca’s Therapies In Diabetes Trials
• Negative Sentiment: Investors also appeared disappointed that Novo’s ADA conference updates did not materially improve the company’s near-term competitive outlook, contributing to the stock’s weakness. Article: Novo Nordisk shares retreat after ADA conference updates fail to excite investors (NVO)

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.